We would rather tell you no than put you on a medication that is not right for you
Another shot we offer at LIVation is a GLP-1 agonist, but it is also a GIP agonist, meaning it works on both your GLP-1 receptor and gastric inhibitory polypeptide receptor
It is approved for individuals with a body mass index (BMI) of 30 or higher, or for those with a BMI of 27 or higher who also have at least one weight-related condition such as high blood pressure, high cholesterol, or sleep apnea
SGLT2 Inhibitors There are several cardiovascular outcome trials testing the efficacy of SGLT2-i as listed in Table 3 and Table 4
Case Examples and Real-World Perspectives To contextualize the metrics above, we highlight several real-world examples and case studies that show how GLP-1 access issues play out in practice from employer-sponsored solutions to patient/provider strategies
They are best understood as metabolic support and are not hormone therapy